Imperium, Revealed: What Stock Is Adam O’Dell Teasing in Green Zone Fortunes?
Adam O’Dell and Money & Markets are pushing Imperium, the Green Zone Fortunes pitch built around the DNA revolution. We identify the company behind it and test the claims.

Adam O’Dell and Money & Markets are pushing Imperium, the Green Zone Fortunes pitch built around the DNA revolution. We identify the company behind it and test the claims.

One promotion, several names — all of them point to the same pitch, and the same stock.
“Imperium: Mankind’s Next Great Leap Forward — Adam O’Dell” is the headline on Money & Markets’ promotion, fronted by analyst Adam O’Dell. The paid publication behind it is Green Zone Fortunes, and the broader report is offered under the title “Beyond Nvidia: The World’s Next #1 Stock.”
The pitch says the next giant stock won’t be Nvidia but a company riding a DNA revolution, framed elsewhere as 2027’s hidden megatrend and a new technological leap for humanity. It promises a way to get in early on that supposed next #1 stock.
The primary stock is identified below with 96/100 confidence. The clues point strongly to Twist Bioscience.
The promotion gives away a remarkably specific trail: a silicon DNA-synthesis platform built around nanowells, claims of extraordinary throughput, an Atlas spinout, a DARPA connection and a quote from scientist Robert Carnahan. It also waves around a partner roster including Microsoft, Illumina, Johns Hopkins and Amazon.
The same pitch is also branded as “2027’s hidden megatrend,” “DNA Millionaire Bundle,” “Beyond AI” and “DNA Revolution.” Those names refer to the same underlying DNA-revolution promotion, not four separate discoveries.
The main stock is Twist Bioscience Corp. (TWST). The strongest match is the silicon DNA-synthesis platform: Twist’s investor materials discuss its nanowell architecture and the scale and throughput it enables, while the company’s technology page describes the same platform in language strikingly close to the promotion.
The DARPA clue is even harder to mistake. Twist’s biopharma-solutions page quotes Robert Carnahan saying, “Twist is the only synthetic DNA provider who can deliver the quantity and quality of DNA we need for our projects rapidly.” Twist’s May 2025 Form 8-K also documents the Atlas spinout, royalty rights and an equity interest representing approximately 24% of Atlas’s fully diluted capital. The promotion rounds that to 25%, but the corporate filing supplies the unmistakable match.
Two bonus reports in the offer point to thinner, less certain identifications. “The Microsoft of the $65 Trillion DNA Revolution” is most plausibly Ginkgo Bioworks (DNA), rated 76/100, while “The #1 DNA ‘App’ Set to Cure Balding” is most plausibly Absci (ABSI), rated 82/100. Those are guesses, not conclusions: Ginkgo fits the operating-system framing, and Absci fits the hair-loss program and Eli Lilly investment, but both teasers contain clear promotional errors.
The offer bundles 2 bonus reports that tease their own stocks. These get a sentence or two of copy each, so the evidence is much thinner than for the main pick and what follows is our best reading rather than a confident answer.
| Bonus report | Our best guess | Confidence |
|---|---|---|
| The Microsoft of the $65 Trillion DNA Revolution | DNA — Ginkgo Bioworks Holdings | 76/100 — solid |
| The #1 DNA ‘App’ Set to Cure Balding | ABSI — Absci Corp | 82/100 — solid |
The claim-by-claim check below separates the pieces that match Twist’s filings and company materials from the places where the promotion inflates a figure, broadens a relationship or turns a technical distinction into a superlative. The key sources are Twist’s Form 10-K, May 2025 Form 8-K, shareholder presentations, earnings materials and technology pages, alongside partner announcements and SEC filings.
| The promotion claims | Verdict | What we found |
|---|---|---|
| The company is worth over 600 times less than Nvidia. | Contradicted | TWST had a market capitalization of about $7.50 billion while Nvidia had about $3.92 trillion, making Twist roughly 523 times smaller rather than more than 600 times smaller. |
| Twist's revenue rose for fourteen consecutive quarters. | Checks out | Twist's Q3 FY2026 shareholder presentation explicitly reported 14 consecutive quarters of sequential revenue growth; its next quarterly release described the following period as the 15th consecutive quarter. |
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
This is the third Adam O’Dell promotion we’ve identified. The first two, “Super Startup” and “America’s New Power Grid,” both pointed to Albemarle Corporation (ALB), which is down 1.25% since we revealed it. That’s a small ledger, but it’s the ledger.
The pitch’s central claim is that DNA synthesis is about to become the next Nvidia-scale platform, and Twist is the best way to own that leap.
The first link holds. Twist has a real silicon-based DNA-synthesis platform, reported 14 consecutive quarters of sequential revenue growth in its Q3 FY2026 shareholder presentation, and has built genuine relationships across biotech, cloud computing and data storage. The DARPA quote and Atlas spinout are not vapor; they’re traceable in Twist’s own materials and filings.
The weakest link is the jump from “real platform” to “inevitable next #1 stock.” The promotion says Twist is more than 600 times smaller than Nvidia, but the cited market capitalizations make it roughly 523 times smaller. It says the nanowells are 10,000 times faster, while Twist’s materials support up to 10,000 times greater scale and throughput in one comparison and 1,000 times greater throughput on its technology page. Those are big differences wearing the same costume. The $65 trillion DNA-market framing is weaker still: published industry estimates cited in the check do not support a DNA-only opportunity of that size.
How confident are we? 96 out of 100. We identified Twist Bioscience Corp (TWST) from the promotion's own clues and checked 17 of its claims against filings, earnings calls, ownership records, market data and public reporting. This is our analysis, not the publisher's disclosure — we have no relationship with them.
Knowing which stock it is only gets you halfway. We score TWST on valuation, profitability, growth, financial health and momentum — and reach our own conclusion, independent of how it was sold to you.
Read the TWST report →Independent of the promotion — our own numbers, score and analysis.
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
| The silicon nanowell platform delivers 10,000 times the prior technology's speed. | Overstated | Twist's investor presentation claimed up to 10,000 times greater scale and throughput than a 96-well approach, while its technology page cited 1,000 times greater throughput; neither supports 10,000 times faster processing. |
| The microchip cannot be copied because an iron-clad patent protects it. | Overstated | Twist's FY2025 Form 10-K reported more than 200 issued or allowed patents and more than 250 pending applications, including DNA-synthesis patents and nanowell families, but that patent estate does not make the technology literally impossible to copy or design around. |
| Twist spun out Atlas with a 25% stake and royalty rights. | Overstated | Twist's May 2025 Form 8-K documented the Atlas spinout, royalty rights and an equity interest representing approximately 24% of Atlas's fully diluted capital, not exactly 25%. |
| Twist partnered with Amazon. | Overstated | An Amazon Web Services industry article described Twist as the wet-lab partner behind Amazon Bio Discovery validations, and Twist's earnings call cited work involving Amazon, but the record supports a project relationship rather than the broad standalone partnership implied by the promotion. |
| Twist partnered with Microsoft. | Checks out | Twist, Illumina and Western Digital announced an alliance with Microsoft in October 2020 to advance DNA data storage, according to Twist's investor-relations release. |
| Twist partnered with Johns Hopkins. | Checks out | AWS identified Twist as the wet-lab CRO partner for an antibody-developability benchmark developed jointly with Johns Hopkins University, establishing a project-level Twist–Johns Hopkins relationship. |
| Twist partnered with Illumina. | Checks out | Twist's October 2020 announcement said Twist, Illumina and Western Digital formed an alliance with Microsoft to advance DNA data storage. |
| DARPA scientist Robert Carnahan said Twist was the only provider able to deliver the needed DNA rapidly. | Checks out | Twist's biopharma-solutions page quotes Robert Carnahan, PhD, saying, “Twist is the only synthetic DNA provider who can deliver the quantity and quality of DNA we need for our projects rapidly.” |
| Ginkgo was founded by five MIT PhDs. | Checks out | Reshma Shetty's 2015 testimony to the U.S. House said Ginkgo Bioworks was founded in 2008 by a team of five MIT PhDs, while later Ginkgo materials describe four PhD students and their professor Tom Knight. |
| Ginkgo is the operating-system layer of the DNA revolution. | Checks out | Ginkgo investor materials describe a horizontal platform for programming cells, and CEO Jason Kelly compared the company's intended role to AWS and Windows as universal infrastructure for programming biology. |
| Ginkgo developed applications alongside Bayer, Syngenta and Merck. | Checks out | Bayer announced a multi-year strategic partnership with Ginkgo for agricultural biologicals, Syngenta disclosed collaboration on next-generation seed technology and biologicals, and Merck announced Ginkgo collaborations on API and biologics manufacturing. |
| The DNA revolution represents a $65 trillion opportunity. | Contradicted | McKinsey Global Institute estimates $2 trillion to $4 trillion of direct annual Bio Revolution impact in 2030–2040, Grand View Research forecasts a $69.2 billion synthetic-biology market in 2033, and BCG discusses disruption of industries representing up to 30% of GDP; none supports a $65 trillion DNA-only market forecast. |
| Absci is developing a genetic treatment that switches off male-pattern baldness. | Contradicted | Absci's SEC prospectus describes ABS-201 as an AI-designed anti-PRLR antibody being developed for androgenetic alopecia and endometriosis; it is a biologic antibody program, not a genetic or gene-silencing treatment. |
| Eli Lilly bought a large stake in Absci. | Checks out | Absci disclosed in SEC offering documents that Eli Lilly made a $40 million strategic investment within a $100 million financing, a substantial portion of the offering. |
| A key Absci hair-loss catalyst was only weeks away. | Checks out | Absci's Q3 2026 Form 10-Q and November corporate presentation said interim ABS-201 proof-of-concept data were expected in December 2026, which was only weeks away as of November 13, 2026. |
Cancel anytime

Twist Bioscience Corporation (TWST) beat earnings and revenue estimates, yet the stock drops as investors weigh valuation, margin progress and growth expectations. This deep-dive examines the company’s 15th straight quarter of sequential revenue growth, AI drug discovery momentum, NGS expansion and the path toward sustained profitability.

Twist Bioscience Corporation (TWST) falls after earnings beats, with shares down 12.0% as investors react to the latest quarterly results and outlook.

Twist Bioscience is posting strong revenue growth and improving margins, but valuation remains demanding. The stock earns a Hold as the company works toward adjusted EBITDA breakeven in fiscal Q4 2026.